Detalles de la búsqueda
1.
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.
Eur J Nucl Med Mol Imaging
; 51(5): 1361-1370, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38114616
2.
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy.
Ann Hematol
; 103(1): 259-268, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37861736
3.
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Blood
; 138(24): 2499-2513, 2021 12 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34166502
4.
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy.
Cytotherapy
; 25(9): 986-992, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37055322
5.
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy.
Eur J Nucl Med Mol Imaging
; 50(5): 1406-1413, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36513818
6.
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies.
Haematologica
; 107(9): 2096-2107, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35172565
7.
Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report.
BMC Infect Dis
; 21(1): 121, 2021 Jan 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-33509115
8.
Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL.
Blood
; 140(20): 2175-2179, 2022 11 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35776908
9.
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
J Clin Oncol
; 42(2): 205-217, 2024 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37874957
10.
Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria.
Cancer Imaging
; 23(1): 44, 2023 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37189191
11.
Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy.
J Immunother Cancer
; 11(10)2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37880181
12.
Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy.
Cancer Immunol Res
; 11(6): 707-719, 2023 06 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37040425
13.
Functional connectivity MRI provides an imaging correlate for chimeric antigen receptor T-cell-associated neurotoxicity.
Neurooncol Adv
; 5(1): vdad135, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38024243
14.
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use.
Hemasphere
; 7(8): e907, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37449196
15.
Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL.
Hemasphere
; 7(4): e858, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37038465
16.
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.
Sci Adv
; 9(38): eadg3919, 2023 09 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-37738350
17.
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.
Nat Med
; 29(4): 906-916, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36914893
18.
Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment.
Blood Adv
; 6(10): 3022-3026, 2022 05 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35042236
19.
Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells.
Neurology
; 98(21): 884-889, 2022 05 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35351785
20.
Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment.
Front Oncol
; 12: 974029, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36158658